Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 108
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.01-028 - Overestimation with Cox HR - Cox-TEL-Adjusted Associations of PD-L1 Expression with Immune Checkpoint Inhibitor Survival Benefit in Lung Cancer
Author(s): Emily Pei-Ying Lin- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 171
- Coordinates: 8/07/2022, 09:45 - 18:00, Exhibit Hall - Hall B
-
+
EP08.02-127 - Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
Author(s): Bin-Chi Liao- Abstract
Loading... -
+
EP08.02-029 - Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations: Effect of Prior Treatment
Author(s): James Chih-Hsin Yang- Abstract
Loading... -
+
EP08.02-140 - MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
Author(s): Myung-Ju Ahn- Abstract
Loading...
-
+
OA03 - Molecular Targeted Treatments
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 11
- Moderators:Andrew Ciupek
- Coordinates: 8/07/2022, 14:30 - 15:40, Hall C7
-
+
OA03.05 - Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
14:52 - 15:02 | Author(s): Michael Thomas
- Abstract
Loading...
-
+
OA12 - Novel and Combination Strategies for SCLC
- Type: Oral
- Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
- Presentations: 10
- Moderators:Alessandra Curioni-Fontecedro
- Coordinates: 8/08/2022, 16:00 - 17:00, Hall C8
-
+
OA12.06 - First-Line Pembrolizumab or Placebo Combined With Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
16:32 - 16:42 | Author(s): Charles M Rudin
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Presentations: 10
- Moderators:Pilar Garrido
- Coordinates: 8/09/2022, 14:30 - 15:30, Hall C7
-
+
OA15.03 - Avelumab vs Chemotherapy for First-line Treatment of Advanced PD-L1+ NSCLC: Primary Analysis from JAVELIN Lung 100
14:32 - 14:42 | Author(s): Martin Reck
- Abstract
Loading...
